ENO2 and colorectal cancer: Before the radiological evaluation, if the serum tumor markers CYFRA211/NSE/SCC increased by 12% for lung squamous carcinoma, CEA/CA125 increased by 29% for lung adenocarcinoma, CA125/CA724/CA199/CEA increased by 49% for colorectal cancer, CA199 increased by 167% for pancreatic cancer, and CA199 increased by 126% for cholangiocarcinoma accordingly per month from the baseline, the possibility of HPD of the patient was considered to be high.